Company intelligence / Profile preview

NsGene

Ownership: Private
Development stage: Other

Overview

NsGene developed an encapsulated cell therapy platform to deliver biologics directly to the brain for the treatment of neurological disorders. Its lead candidate, targeting p75NTR for Alzheimer’s disease, reached Phase 1 clinical trials. Other programs included recombinant human meteorin for Huntington's disease and neublastin/GDNF-based therapies for sciatica and Parkinson's; some have been discontinued. The company partnered with Takeda on GDNF delivery in Parkinson's and completed initial clinical studies in Alzheimer's[2][4][5].

Therapeutic areas: Neurology
Modalities: Cell therapyGene therapyBiologicRecombinant proteinDevice (implantable drug delivery)
Industry: Biotech

Drug pipeline

1 asset

NsG0202

Partnerships

Takeda Pharmaceutical Company Limited [5]Michael J. Fox Foundation grant support [4]

Beyond the preview

Go deeper on NsGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NsGene.